N- ((5- (methanesulfonyl)pyridin- 2- yl)methyl)- 6- methyl- 5- (1- methyl- 1H- pyrazol- 5- yl)- 2- oxo- 1- (3- (trifluoromethyl)phenyl)- 1,2- dihydropyridine- 3- carboxamide

04/01/2013 - "Efficacy and safety of AZD9668 60 mg twice daily over 4 weeks were evaluated in a randomised, double-blind, placebo-controlled, parallel-group, Phase II, signal-searching study in patients with bronchiectasis. "
04/01/2013 - "In this small signal-searching study, 4 weeks' treatment with AZD9668 improved lung function in patients with bronchiectasis and there were trends for reductions in sputum inflammatory biomarkers. "
04/01/2013 - "Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis."
04/01/2012 - "The most advanced compound from these classes, AZD9668, has been reported to show significant effects on relevant biomarkers in bronchiectasis and cystic fibrosis patient populations."
10/01/2011 - "N-{[5-(methanesulfonyl)pyridin-2-yl]methyl}-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (AZD9668) is a novel, oral inhibitor of neutrophil elastase (NE), an enzyme implicated in the signs, symptoms, and disease progression in NE-driven respiratory diseases such as bronchiectasis and chronic obstructive pulmonary disease via its role in the inflammatory process, mucus overproduction, and lung tissue damage. "

10/05/2023 - "We found AZD9668 treated PyMT-NE+/+ mice showed significantly reduced lung metastases, improved recurrence-free, metastasis-free and overall survival, and their tumors showed similar molecular alterations as those observed in PyMT-NE-/- tumors. "

10/05/2023 - "To evaluate whether pharmacological inhibition of NE inhibited pulmonary metastasis and phenotypically mimicked PyMT NE-/- mice, we utilized AZD9668, a clinically available and specific NE inhibitor. "
10/05/2023 - "We found AZD9668 treated PyMT-NE+/+ mice showed significantly reduced lung metastases, improved recurrence-free, metastasis-free and overall survival, and their tumors showed similar molecular alterations as those observed in PyMT-NE-/- tumors. "

06/01/2015 - "Feasibility of Computed Tomography in a Multicenter COPD Trial: A Study of the Effect of AZD9668 on Structural Airway Changes."
04/01/2013 - "PK and safety/tolerability profile of AZD9668 were studied in 107 healthy Caucasian and Japanese volunteers and 18 patients with COPD in three double-blind, randomized, placebo-controlled studies with single and multiple exposure to AZD9668 for up to 14 days. "
04/01/2013 - "The PK profile of AZD9668 was established in Caucasian and Japanese healthy volunteers and in patients with COPD. "
06/01/2015 - "This was a 12-week, randomized, double-blind, placebo-controlled, Phase IIb trial using CT to investigate the effect of a novel, oral, reversible neutrophil elastase inhibitor, AZD9668 60 mg twice daily (BID), on structural airway changes in patients aged 50-80 years with chronic obstructive pulmonary disease (COPD) (ex-smokers). "
04/01/2012 - "Efficacy, safety and tolerability of AZD9668 (5, 20 and 60 mg bid) were compared with placebo in a randomised, double-blind, placebo-controlled, 12-week, Phase IIb trial (NCT00949975: approved by an Investigational Review Board), in patients with symptomatic COPD receiving maintenance tiotropium. "

10/01/2012 - "The aim of this study was to evaluate the safety and effect on clinical outcomes and biomarkers of inflammation and tissue damage of the neutrophil elastase inhibitor AZD9668 (60 mg twice daily orally for 4 weeks) in cystic fibrosis. "
04/01/2012 - "AZD9668 60 mg bid showed no clinical benefit and no effect on biomarkers of inflammation or tissue degradation when added to tiotropium in patients with COPD. "